INSIDE PHARMA

INSIDE PHARMA

Share this post

INSIDE PHARMA
INSIDE PHARMA
Update on 76471 RE: 76418 FDA Freedom of Information Act Appeal: FOIA 2024-5142

Update on 76471 RE: 76418 FDA Freedom of Information Act Appeal: FOIA 2024-5142

The information and concerns you shared in your messages were forwarded to the appropriate staff within FDA’s Center for Biologics Evaluation and Research (CBER).

Hedley Rees's avatar
Hedley Rees
Jun 28, 2024
∙ Paid
11

Share this post

INSIDE PHARMA
INSIDE PHARMA
Update on 76471 RE: 76418 FDA Freedom of Information Act Appeal: FOIA 2024-5142
5
4
Share

INSIDE PHARMA is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

More news from FDA

Following on from yesterday’s post below:

FDA has responded to my questions on a Manufacturing Facility Inspections FOIA—It's not Good News...

FDA has responded to my questions on a Manufacturing Facility Inspections FOIA—It's not Good News...

Hedley Rees
·
June 27, 2024
Read full story

I received an email this morning as so:

“Dear Hedley:

Thank you for your follow-up message to the U.S. Food and Drug Administration (FDA). Your email has been forwarded to FDA’s Center for Biologics Evaluation and Research (CBER) for response. One of seven centers within the FDA, CBER is responsible for the regulation of many biologically-derived products, including blood intended for transfusion, blood components and derivatives, vaccines, allergenic products, tissue, and cell and gene therapy products.

The information and concerns you shared in your messages were forwarded to the appropriate staff within FDA’s Center for Biologics Evaluation and Research (CBER). Should there be the need for follow up on the information you provided, someone may contact you to obtain further information.

Please kn…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Hedley Rees
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share